USPTO serial 79335233
Reviewed by CopyMark Law Group
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bruce S. Londa
Bruce S. Londa Norris McLaughlin, P.A.7 Times Square21st FloorNew York, NY 10036| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in biotechnological product development; chemicals for use in biotechnological manufacturing processes; chemical preparations, namely, biologically compatible chemical substances for scientific, laboratory, clinical and medical research; biological tissue, namely, mammalian soft and hard tissues comprising or derived from stem cells or progenitor cells for scientific, laboratory, clinical and medical research; biological tissue, namely, biological tissue comprising or derived from stem cells or progenitor cells, and compositions thereof, for scientific, laboratory, clinical and medical research | ACTIVE | — |
| 005 | Pharmaceuticals, namely, pharmaceutical preparations for the treatment of cancer and neurological diseases; medical and veterinary preparations for treatment of cancer and neurological diseases; sanitary preparations for medical purposes; dietetic food and dietetic preparations adapted for medical or veterinary use; dietary supplements for human beings and animals; dietary supplements; pharmaceuticals for use in oncology for the treatment of cancer and neurological diseases | ACTIVE | — |
| 042 | Drug discovery and pharmaceutical drug development services; scientific services in the nature of scientific research, analysis, and testing in the field of pharmaceuticals and research, development and design relating thereto; medical research; technological services in the nature of pharmaceutical products development and technical consulting in the field of pharmaceutical studies and research and design relating thereto; product design and development of medical technology; product design and development of medical diagnostic apparatus; consultancy services in the field of technological development in the field of medical technology and pharmaceuticals; industrial analysis and industrial research services in the field of medical technology and pharmaceuticals; design and development of computer hardware and software; design and development of software; clinical research, namely, conducting clinical trials for others; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibodies, immuno-oncology, inflammation, haematology and infectious disease; medical and scientific research, namely, conducting clinical trials for others; conducting clinical trials for pharmaceutical products for others; scientific screening and assaying, namely, scientific research; chemical analysis; chemical research; biotechnology research; consultancy in the field of biotechnology | ACTIVE | — |
| 044 | Medical services; diagnostic and prognostic medical services; veterinary services; medical analysis services relating to the treatment of persons; pharmaceutical advice; medical and health services relating to antibodies, immuno-oncology, inflammation, haematology and infectious disease, namely, medical diagnostic testing, monitoring and reporting services; medical screening and assaying in the nature of medical testing for diagnostic or treatment purposes | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| May 17, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 20, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 20, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 3, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 2, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 29, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 3, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 3, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 18, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 18, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 28, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 15, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 8, 2022 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Sep 8, 2022 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Sep 7, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 7, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 7, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 7, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 16, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 16, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 3, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 2, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 31, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 15, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 11, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 10, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |